Bristol Myers Squibb announced that it has priced a public offering of senior unsecured notes with a total aggregate principal amount of €5 billion.

The notes will be issued by the company’s wholly owned subsidiary, BMS Ireland Capital Funding Designated Activity Company, in five tranches, including €750 million of 2.973 per cent notes due 2030, €1.15 billion of 3.363 per cent notes due 2033, €1.15 billion of 3.857 per cent notes due 2038, €750 million of 4.289 per cent notes due 2045, and €1.2 billion of 4.581 per cent notes due 2055.

All notes will be fully and unconditionally guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company. The offering is expected to close on November 10, 2025, subject to customary closing conditions.

On November 3, 2025, Bristol Myers Squibb launched a tender offer to purchase, for cash, various series of its outstanding notes. The company intends to use the net proceeds from the new offering, along with approximately $3 billion of cash on hand, to fund the tender offer and other potential repurchases, repayments, or redemptions of existing notes.

Additional proceeds will be used to cover related fees and expenses, with any remaining funds allocated for general corporate purposes. The offering is not contingent upon the completion of the tender offer or the purchase of any notes subject to it.

Citigroup Global Markets Limited, Barclays Bank PLC, BNP Paribas, J.P. Morgan Securities plc, and Société Générale are acting as joint lead managers and book-running managers for the offering.